Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — UCBE Analyst & Investor Event 2013
28 slides from Stablecoin Development's conference presentation, Sep 17, 2013
Slide 1: Beyond Antibiotics
Beyond Antibiotics Ron Najafi, Ph.D. Chief Executive Officer Thomas J. Paulson & Chief Financial Officer — UCBE Analyst & Investor _ om Event yy September 17, 2013
Slide 2: Megatrend - Antibiotic Resistance Crisis
Megatrend - Antibiotic Resistance Crisis Post-Antibiotic Era - Wonder Drugs “ "3 - Save Millions of Lives vie en. if - LE~80 Bacteria containing - Pre-1930s . NOM Lenore: - Minor injury = Death $ - Life Expectancy (LE) ~55 Megatrend Alexander Fleming Bread Mold Observation N@vaBay
Slide 3: Two Distinct Anti-Infective Product Groups
Two Distinct Anti-Infective Product Groups N’®vaBay i PHARMA Aganocides° ‘ NeutroPhase® Lead: Auriclosene Chronic Non- (NVC-422) Healing Wounds / \ || } Dermatology eee : como Impeti ink Eye 1 = impetigo : = \ ww: ~$400M Urology 4 7 UCBE US: ~$100M ice == =——— N@vaBay 2
Slide 4: Pipeline Continues to Advance
Pipeline Continues to Advance Results From Three Advanced Clinical Trials Expected in the Next 3 to 9 Months Therapeutic 2018 2014 Area Scope (Patients) Delivery Urology (ucBE) eutscece) Dermatology Topical fedncieene) (Impetigo) Ga GALDERMA Ophthalmology Global . " Eyed Enrolling Global Phase 2b* (
Slide 5: Anticipated Upcoming Milestones
Anticipated Upcoming Milestones* Yea Date | Event H1 NeutroPhase Partnerships USA / ROW. 2013 H2 Data - Part 2 of Phase 2a Urology (UCBE) H2 Data - Phase 2b Impetigo Global study H1 Data - Phase 2b BAYnovation Global Study H1 Sign Conjunctivitis Partner 2014 H1 Initiate Impetigo Phase 3 Global Studi
Slide 6: Financial Overview
Financial Overview Key Statistics Market Cap (9/16/13) 6/30/13 Cash and Equivalents (Plus an additional ~$1M of Acc/Rec from Partners) Debt Shares Outstanding (only common outstanding) $11.4 N@vaBay
Slide 7: Auriclosene For Prevention of Urinary Catheter Blockage & Encrustation
Auriclosene For Prevention of Urinary Catheter Blockage & Encrustation: Results From Clinical Study CL1001 Keith Bley, PhD Senior Vice President of Product Development NovaBay Pharmaceuticals N™vaBay N@vaBay
Slide 8: Auriclosene (NVC-422)
Auriclosene (NVC-422) HG _CHs ChN SO3Na e N,N-dichloro-2,2-dimethyltaurine is a stable analog of endogenous compounds produced by neutrophils to destroy bacteria e Fast-acting, broad spectrum antimicrobial e Three active INDs: conjunctivitis, skin infections, and urology e > 1300 subjects exposed to
Slide 9: Clinical Studies With Auriclosene
Clinical Studies With Auriclosene Irrigation Solution in Urology e Phase 1 — Safety study in 29 healthy volunteers (CLO703) — 100 mL of 0.01 to 0.1% auriclosene instilled into bladder for 15 minutes — Dosed once daily for up to 7 days e Phase 2 1. Effects on bacteriuria in 20 chronically catheterize
Slide 10: CL1001 Synopsis
CL1001 Synopsis e Objective: Assess the ability of Auriclosene Irrigation Solution to prevent or reduce the blockage and encrustation of indwelling urinary catheters ¢ Population: Patients with indwelling transurethral or suprapubic urinary catheters who have a recent history of urinary catheter enc
Slide 11: CL1001 Design
CL1001 Design © Double-blind, crossover design, multi-center study e Subjects randomized to receive one study solution (0.2% auriclosene or saline) for the first treatment regimen and, after a washout period (7 to 21 days), crossed over to receive the other solution for the second treatment regimen
Slide 12: Can Catheter Irrigation Solution Prevent Blockage and Encrustation?
Can Catheter Irrigation Solution Prevent Blockage and Encrustation? Irrigate catheter with 25 mL of Auriclosene Irrigation Solution or saline for 15 minutes, then repeat Perform irrigation procedure twice per week N™vaBay N@vapay !
Slide 13: Key Inclusion Criteria
Key Inclusion Criteria ¢ Patient (age > 18 years) requiring an indwelling transurethral or suprapubic catheter who has a history over the past year of two or more episodes of catheter blockage and/or encrustation ¢ Urine pH of 2 6.9 or a urine pH 2 6.5 and presence of at least one urease-producing b
Slide 14: Key Exclusion Criteria
Key Exclusion Criteria ¢ Subject with T6 lesion or above and recent history of significant autonomic dysreflexia (requiring intervention or treatment) or found to have significant autonomic dysreflexia with a screening irrigation test procedure e Significant bladder stone formation present prior to
Slide 15: Subject Demographics
Subject Demographics Part 1 Part 2 Part 3 Total N=20 | N=28 | N=19 | N=67 Mean 46.0 462 | 480 | 466 Age (years) : Range 23-75 | 21-76 | 22-81 | 21-81 Gender Male 17 (85%) 19 (68%) 14 (74%) 50 (75%) Diagnosis a 20 (100%) 26 (93%) 17 (89%) 63 (94%) Transurethral | 15 (75%) 13 (46%) 6 (32%) 34 (51%) Ca
Slide 16: Measurement of Catheter Encrustation
Measurement of Catheter Encrustation e After removal, catheter shipped on ice to central laboratory e Catheters sectioned at EH, CS1, CS2, and others as needed ¢ Allsections were imaged using StereoZoom — Luminal area highlighted red (encrusted) or blue (not encrusted) in Photoshop — Analyzed on UN-
Slide 17: Example of Encrustation Measurement
Example of Encrustation Measurement Calculated percentage area of encrustation = 31.4% ¢ Maximal encrustation at any point used as primary measurement, as best reflects loss of catheter patency * Calculated with UN-SCAN-IT PnARA N@vaBay 16
Slide 18: Results From Clinical Study CL1001
Results From Clinical Study CL1001 N™vaBay
Slide 19: Difference in Encrustation Per Subject
Difference in Encrustation Per Subject in Part 1 (Preliminary formulation; 3X per week for 2 weeks) Benefit Saline Auriclosene Saline - NVC 422 Percentage encrustation saline minus % encrustation auriclosene N™vaBay NDvaBay 1g:
Slide 20: Effects of Auriclosene Irrigation Solution on Catheter Encrustation in Part 2
Effects of Auriclosene Irrigation Solution on Catheter Encrustation in Part 2 (3x per week for 2 weeks) Benefit Saline__Auriclosene 0 Saline -NVC422 Percentage encrustation saline minus % encrustation auriclosene N‘°evaBay N@vaBay 199
Slide 21: Auriclosene Irrigation Solution Decreased Catheter Encrustation in Part 3
Auriclosene trrigation Solution Decreased Catheter Encrustation in Part 3 (2x pe week for-4 weeks) Benefit =) _ agp Saline Auriclosene Wilcoxon signed-rank test p<0.001 -100 -75 -50) - te) Saline -NVO-422 Percentage encrustation saline minus % encrustation auriclosene N‘°evaBay N@vaBay 790
Slide 22: Auriclosene Irrigation Solution Reduces Maximum Percent Area of Encrustation
Auriclosene Irrigation Solution Reduces Maximum Percent Area of Encrustation 14 Auriclosene Saline Mean percentage 21.7 76.9 encrustation | 95% Cl (2.1, 41.2) (54.9, 98.8) N@vaBay mh
Slide 23: Auriclosene Reduces Catheter Blockages & Complete Encrustation
Auriclosene Reduces Catheter Blockages & Complete Encrustation N=14 Auriclosene| Saline | P-Value Percent of catheters removed for clinical 14.3% 64.3% 0.016* blockage Percent of removed catheters that have 64.3% 0.003* 100% encrustation N™vaBay * Using McNemar exact test; N = 14 N@vaBay 772
Slide 24: Safety & Adverse Events
Safety & Adverse Events e There were no SAEs ¢ More bladder AEs were observed following treatment with auriclosene than with saline e All treatment-related AEs (including any symptoms of irrigation-induced autonomic dysreflexia with saline or auriclosene) were mild or moderate in severity, transient
Slide 25: Bacteria Give Rise to Crystalline Biofilm
Bacteria Give Rise to Crystalline Biofilm — Urease g Urea HoN@ SNH» i: Struvite Hydroxyapatite crystals crystals S rm esx: Crystalline biofilm / iia Catheter encrustation Sediment Bladder stones Snare N@vaBay 24
Slide 26: Auriclosene Kills Bacteria and Reduces Crystalline Biofilm Accumulation
Auriclosene Kills Bacteria and Reduces Crystalline Biofilm Accumulation Auriclosene Struvite Hydroxyapatite crystals crystals eo eS Crystalline biofilm Qe Catheter encrustation Sediment Bladder stones N@vaBay N@vaBay 25
Slide 27: Summary and Conclusions
Summary and Conclusions e Auriclosene Irrigation Solution used twice per week significantly reduces encrustation and blockage in indwelling urinary catheters ° No significant safety or tolerability issues have been identified e Future pivotal clinical studies will seek to provide additional evidence
Slide 28: Auriclosene For Prevention of Urinary Catheter Encrustation
Auriclosene For Prevention of Urinary Catheter Encrustation: Results From Clinical Study CL1001 Keith Bley, PhD Senior Vice President of Product Development NovaBay Pharmaceuticals N™vaBay N@vaBay 27
NovaBay Pharmaceuticals — UCBE Analyst & Investor Event 2013 on 6ix